ICX Intercytex

 

TIDMICX 
 
RNS Number : 6686E 
Intercytex Group plc 
23 December 2009 
 

23 December 2009 
 
 
Intercytex Group plc - result of General Meeting 
 
 
Intercytex Group plc (AIM: ICX) ("Intercytex") confirms that at the General 
Meeting held earlier today, all the Resolutions, set out in the circular sent to 
shareholders on 7 December 2009, were duly passed. Cancellation of admission to 
trading on AIM is therefore expected to occur at 7.00 a.m. on 8th January 2010. 
The Company's name will also be changed to Regenerative Medicine Assets Limited. 
In addition, as set out in the circular, Dr Paul Kemp and Dr Alan Suggett have 
resigned as directors of Intercytex, The Board wishes to thank both Alan and 
Paul for their contributions to the Company. 
 
 
- Ends - 
 
 
Enquiries 
 
 
For more information, contact: 
 
 
+--------------------------------------------+--------------------------------------------+ 
| Intercytex Group plc                       |                                            | 
+--------------------------------------------+--------------------------------------------+ 
| Nick Higgins, Chief Executive Officer      | Tel: 0161 904 4500                         | 
+--------------------------------------------+--------------------------------------------+ 
| Max Herrmann, Chief Financial Officer      |                                            | 
+--------------------------------------------+--------------------------------------------+ 
|                                            |                                            | 
+--------------------------------------------+--------------------------------------------+ 
| Financial Dynamics                         |                                            | 
+--------------------------------------------+--------------------------------------------+ 
| Jonathan Birt                              | Tel: 0207 269 7205                         | 
+--------------------------------------------+--------------------------------------------+ 
|                                            |                                            | 
+--------------------------------------------+--------------------------------------------+ 
| Piper Jaffray Ltd                          |                                            | 
+--------------------------------------------+--------------------------------------------+ 
| Neil Mackison                              | Tel: 0203 142 8700                         | 
| Graeme Smethurst                           |                                            | 
+--------------------------------------------+--------------------------------------------+ 
 
 
Intercytex' shares are listed on the Alternative Investment Market of the London 
Stock Exchange under the ticker symbol ICX.L. 
 
 
Additional information on the Company can be found at www.intercytex.com 
 
 
Statements contained within this press release may contain forward-looking 
information or statements with respect to the financial condition, results of 
operations and business achievements/performance of Intercytex and certain of 
the plans and objectives of management of Intercytex with respect thereto. By 
their nature, forward-looking statements involve risks and uncertainties that 
may cause actual results to vary from those contained in the forward-looking 
statements. In some cases, you can identify such forward-looking statements by 
terminology such as 'may', 'will', 'could', 'forecasts', 'expects', 'plans', 
'anticipates', 'believes', 'estimates', 'predicts', 'potential', 'continue' or 
similar expressions.  A number of factors, including the satisfactory progress 
of research and development, could cause Intercytex' actual financial condition, 
results of operations and business achievements/performance to differ materially 
from the estimates made or implied in such forward-looking statements and, 
accordingly, reliance should not be placed on such statements. Forward 
projections reflect management's best estimates based on information available 
at the time of issue and are not a guarantee of future performance. Other than 
as required by applicable law, Intercytex does not undertake any obligation to 
update or revise any forward-looking information or statements to reflect events 
or circumstances after the date of this release. 
 
 
The term "Intercytex" refers to Intercytex Group plc and its subsidiary 
undertakings. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 ROMEXLFLKLBXFBD 
 

Intercytex (LSE:ICX)
Historical Stock Chart
From Oct 2024 to Nov 2024

Intercytex (LSE:ICX)
Historical Stock Chart
From Nov 2023 to Nov 2024